New hope against Drug-Resistant TB: phase II trial launches

NCT ID NCT07393438

First seen Feb 06, 2026 · Last updated May 24, 2026 · Updated 13 times

Summary

This study tests whether adding acetohydroxamic acid (AHA) to a short-course drug regimen can safely and effectively treat multidrug-resistant tuberculosis (MDR-TB). About 120 adults with confirmed MDR-TB will receive either AHA or a placebo alongside standard antibiotics. The goal is to see if AHA helps clear the bacteria faster and with fewer side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIDRUG-RESISTANT TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Anhui Chest Hospital

    Hefei, Anhui, 230000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-••••

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.